Filtered By:
Drug: Proton Pump Inhibitors PPIs

This page shows you your search results in order of relevance. This is page number 12.

Order by Relevance | Date

Total 238 results found since Jan 2013.

Risk of dementia in elderly patients with the use of proton pump inhibitors.
Authors: Haenisch B, von Holt K, Wiese B, Prokein J, Lange C, Ernst A, Brettschneider C, König HH, Werle J, Weyerer S, Luppa M, Riedel-Heller SG, Fuchs A, Pentzek M, Weeg D, Bickel H, Broich K, Jessen F, Maier W, Scherer M Abstract Drugs that modify the risk of dementia in the elderly are of potential interest for dementia prevention. Proton pump inhibitors (PPIs) are widely used to reduce gastric acid production, but information on the risk of dementia is lacking. We assessed association between the use of PPIs and the risk of dementia in elderly people. Data were derived from a longitudinal, multicenter cohort s...
Source: European Archives of Psychiatry and Clinical Neuroscience - October 25, 2014 Category: Psychiatry Tags: Eur Arch Psychiatry Clin Neurosci Source Type: research

Management of acid-related disorders in patients with dysphagia
Publication date: 6 September 2004 Source:The American Journal of Medicine Supplements, Volume 117, Issue 5, Supplement 1 Author(s): Colin W. Howden Dysphagia affects a large and growing number of individuals in the United States, particularly the elderly and those who are neurologically impaired. Swallowing difficulties may be due to age-related changes in oropharyngeal and esophageal functioning as well as central nervous system diseases such as stroke, Parkinson disease, and dementia. Among institutionalized individuals, dysphagia is associated with increased morbidity and mortality. An appreciation of the physiology ...
Source: The American Journal of Medicine Supplements - November 6, 2014 Category: Drugs & Pharmacology Source Type: research

Analysis of gastrointestinal prophylaxis in patients receiving dual antiplatelet therapy with aspirin and clopidogrel.
CONCLUSION: More than half of the patients did not receive GI prophylaxis appropriately. The most common reason for nonadherence to the consensus document was no prophylaxis when indicated. Vascular events could not be directly attributed to PPI use, and GI events occurred despite prophylaxis. Overall, there was a low incidence of adverse events related to the use of PPI therapy.  PMID: 24456320 [PubMed - indexed for MEDLINE]
Source: Journal of Managed Care Pharmacy - November 14, 2014 Category: Drugs & Pharmacology Tags: J Manag Care Pharm Source Type: research

Effect of omeprazole on the concentration of interleukin-6 and transforming growth factor-β1 in patients receiving dual antiplatelet therapy after percutaneous coronary intervention.
Authors: Hudzik B, Szkodzinski J, Danikiewicz A, Wilczek K, Romanowski W, Lekston A, Polonski L, Zubelewicz-Szkodzinska B Abstract BACKGROUND: Dual antiplatelet therapy (aspirin plus clopidogrel) is recommended in patients undergoing percutaneous coronary intervention (PCI). Treatment with proton pump inhibitors (PPIs) decreases bleeding rate. Alarming reports have been made that PPIs may decrease the antiplatelet activity of clopidogrel. We sought to determine whether levels of interleukin-6 (IL-6) and transforming growth factor-β1 (TGF-β1) might help distinguish individuals at risk for adverse events. METHO...
Source: European Cytokine Network - November 25, 2014 Category: Neuroscience Tags: Eur Cytokine Netw Source Type: research

Conflicting Results Between Randomized Trials and Observational Studies on the Impact of Proton Pump Inhibitors on Cardiovascular Events When Coadministered With Dual Antiplatelet Therapy: Systematic Review Original Articles
Conclusions— Large, well-conducted observational studies of PPIs and randomized controlled trials of omeprazole seem to provide conflicting results for the effect of PPIs on cardiovascular outcomes when coadministered with DAPT. Prospective trials that directly compare pharmacodynamic parameters and clinical events among specific PPI agents in patients with unstable angina/non–ST-segment–elevation myocardial infarction treated with DAPT are warranted.
Source: Circulation: Cardiovascular Quality and Outcomes - January 20, 2015 Category: Cardiology Authors: Melloni, C., Washam, J. B., Jones, W. S., Halim, S. A., Hasselblad, V., Mayer, S. B., Heidenfelder, B. L., Dolor, R. J. Tags: Secondary prevention Original Articles Source Type: research

Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel vs. clopidogrel and managed without revascularization: Insights from the TRILOGY ACS Trial
Conclusions Among ACS patients managed without revascularization, use of PPIs did not result in a differential antiplatelet response between prasugrel vs. clopidogrel but was associated with a lower incidence of MI with prasugrel. These hypothesis-generating findings suggest that factors besides platelet reactivity may underlie the differential risk of MI observed by treatment assignment with PPI use.
Source: American Heart Journal - June 11, 2015 Category: Cardiology Source Type: research

Patterns of Antiplatelet Therapy in Patients Who Have Experienced an Acute Coronary Event: A Descriptive Study in UK Primary Care
Conclusion: Although most patients were prescribed AP therapy in the 90 days following an acute coronary event, a substantial proportion discontinued DAT or ASA monotherapy within 1 year. It is essential that physicians consider strategies to reduce the risk of discontinuation of AP therapy.
Source: Journal of Cardiovascular Pharmacology and Therapeutics - June 17, 2015 Category: Cardiology Authors: Saez, M. E., Gonzalez-Perez, A., Johansson, S., Nagy, P., Rodriguez, L. A. G. Tags: Clinical Studies Source Type: research

Co-Administration of Proton Pump Inhibitors in Chronic Aspirin Users and the Risk of Adverse Cardiovascular Events: a Population-Based Cohort Study
This study investigated the effect of co-administration of PPIs in aspirin users with a first acute myocardial infarction (AMI) or stroke on the risk of recurrence of such a CV event.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: A Tran-Duy, FH Vanmolkot, PC Souverein, AW Hoes, A de Boer, CD Stehower, NJ de Wit, MA Joore, F de Vries Source Type: research

Prognosis of concomitant users of clopidogrel and proton-pump inhibitors in a high-risk population for upper gastrointestinal bleeding.
CONCLUSION: Among patients at high risk of upper GI bleeding, those with a concomitant use of PPIs and clopidogrel were at a decreased risk of mortality, and possibly also a decreased risk of recurrence of cardiovascular disease. PMID: 24731755 [PubMed - indexed for MEDLINE]
Source: BMC Pharmacology and Toxicology - November 20, 2015 Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research

Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review Coronary Heart Disease
Conclusions Several frequently used PPIs previously thought to be safe for concomitant use with clopidogrel were associated with greater risk of adverse cardiovascular events. Although the data are observational, they highlight the need for randomized controlled trials to evaluate the safety of concomitant PPI and clopidogrel use in patients with coronary artery disease.
Source: JAHA:Journal of the American Heart Association - October 29, 2015 Category: Cardiology Authors: Sherwood, M. W., Melloni, C., Jones, W. S., Washam, J. B., Hasselblad, V., Dolor, R. J. Tags: Coronary Heart Disease Source Type: research

Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy
ConclusionsGastroprotection with PPI therapy should be utilized in appropriately selected patients with coronary artery disease requiring DAPT, even if the patients are on low-dose aspirin. (Clopidogrel and the Optimization of Gastrointestinal Events Trial [COGENT]; NCT00557921)
Source: Journal of the American College of Cardiology - April 4, 2016 Category: Cardiology Source Type: research

3 Surprising Things That Increase Your Dementia Risk
SPECIAL FROM “As many as five million Americans age 65 and older may have Alzheimer’s Disease, and that number is expected to double for every five-year interval beyond age 65.” — the National Institute of Neurologic Disorders and Stroke. While Alzheimer’s is the most common form of dementia, it is not the only form. Risk factors for all kinds of dementia include, age, alcohol use, smoking, atherosclerosis, diabetes, hypertension, and genetics. However, researchers have found some startling connections that show other surprising factors that can heighten your risk: Risk Factor #1: Anticho...
Source: Healthy Living - The Huffington Post - May 6, 2016 Category: Consumer Health News Source Type: news

PPI Side Effects Destroying Your Blood Vessels
It seems whenever I turn on my TV these days, there’s Larry the Cable Guy with a quick fix for heartburn. He makes it sound so simple. Just pop a pill, eat all the chili dogs you want, and no more heartburn… at least for a couple of weeks. What Is Heartburn? Heartburn is an irritation of the esophagus that is caused by stomach acid. It has nothing to do with the heart. But a new study has found a link between proton-pump inhibitors (PPIs) — heartburn drugs — and the premature aging of blood vessels. Heartburn Drugs PPI Side Effects Researchers focused on the effects of two PPIs, one of which is Nexium. They...
Source: Al Sears, MD Natural Remedies - June 16, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Heart Health Source Type: news

Nonsteroidal Anti-inflammatory Drug and Aspirin-induced Peptic Ulcer Disease.
Abstract Despite decreasing Helicobacter pylori prevalence, the prevalence of peptic ulcer disease is increasing in the aged population, mainly due to increasing use of NSAIDs to manage pain and inflammation. In addition, low dose aspirin is employed as an anti-coagulant for those who have suffered or are at high risk of ischemic stroke and cardiovascular disease. However, NSAIDs and aspirin are injurious to mucosa of stomach and duodenum. NSAID-induced inhibition of mucosal prostaglandin synthesis is thought to be a major mechanism of gastrointestinal mucosal injury. The proportion of elderly has increased rapidl...
Source: Korean J Gastroenter... - June 19, 2016 Category: Gastroenterology Authors: Shim YK, Kim N Tags: Korean J Gastroenterol Source Type: research

Proton Pump Inhibitors and Dementia Incidence
To the Editor I read with interest the article by Gomm and colleagues, which examined the association between the use of proton pump inhibitors (PPIs) and incident dementia in elderly individuals in a prospective study. The authors adopted time-dependent Cox regression analysis, and the time-dependent covariates were polypharmacy and the comorbidities of depression, diabetes, ischemic heart disease, and stroke. Age and sex were also used as confounding factors. The hazard ratio of PPIs for incident dementia was 1.44 (95% CI, 1.36-1.52), and the authors recommended randomized clinical trials to confirm the causal associatio...
Source: JAMA Neurology - June 20, 2016 Category: Neurology Source Type: research